MENU
+Compare
HELX
ETF ticker: BATS
AS OF
Apr 2, 11:14 AM (EDT)
Price
$26.71
Change
+$0.20 (+0.75%)
Net Assets
10.79M

HELX stock forecast, quote, news & analysis

The investment seeks capital appreciation... Show more

Category: #Health
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Exact Sciences Corp (NASDAQ:EXAS), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Guardant Health (NASDAQ:GH).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF ETF is 40.68B. The market cap for tickers in the group ranges from 138.44M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is FDMT at 138.44M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was 2%. For the same ETF, the average monthly price growth was 9%, and the average quarterly price growth was 95%. CTVA experienced the highest price growth at 3%, while RCKT experienced the biggest fall at -29%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was 31%. For the same stocks of the ETF, the average monthly volume growth was -21% and the average quarterly volume growth was 80%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 70
Price Growth Rating: 67
SMR Rating: 80
Profit Risk Rating: 74
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Franklin Templeton ETF TrustONE FRANKLIN PARKWAYSAN MATEO
Phone
N/A
Web
etf.franklintempleton.com